Iteos Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview

iTeos Therapeutics

04/08/2025 13:56

Iteos Therapeutics Inc ITOS.OQ ITOS.O is expected to  show a fall in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Iteos Therapeutics Inc is for a loss of $1.01 per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Iteos Therapeutics Inc is $10.27, about 1.8% above its last closing price of $10.09

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.86
-0.95
-0.80
Beat
15.9
Dec. 31 2025
-1.05
-1.06
-1.03
Beat
3.2
Sep. 30 2024
-1.15
-0.89
-1.05
Missed
-18.1​
Jun. 30 2024
-1.04
-1.04
-0.18
Beat
82.7
​​Mar. 31 2024
-0.97
-1.26
-1.07
Beat
14.8
Dec. 31 2023
-0.93
-1.03
-0.85
Beat
17.7​
Sep. 30 2023
-1.14
-1.20
-0.90
Beat
25.2
Jun. 30 2023
-0.98
-1.03
-0.96
Beat
6.8

This summary was machine generated August 4 at 12:56 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)